• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment

FirstWordPharmaFebruary 14, 2022

Tag: singapore , Pfizer , Paxlovid

Singapore has received its first batch of Pfizer's oral COVID-19 treatment Paxlovid, after authorities last week said they had approved the tablet for COVID-19 in adults at risk for severe disease, reported CNA.

"This is the first oral antiviral medicine approved for treatment of COVID-19 infection in Singapore," noted said health minister Ong Ye Kung.

Paxlovid cut the risk of COVID-19-related hospitalisations or death by 88.9% when given within three days of symptom onset, according to a Health Sciences Authority (HSA) review of clinical data based on an ongoing Pfizer study.

Previous:Celartics Biopharma announces a new generation mRNA vaccine against COVID-19

Next:EdiGene and Neukio enter collaboration to develop next-generation immune cell therapies

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment - PharmaSources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Paxlovid (PF-07321332)New Chemical Antiviral Drugs Protease Inhibitor

Paxlovid (PF-07321332)New Chemical Antiviral Drugs Protease Inhibitor
Paxlovid

Paxlovid
Paxlovid

Paxlovid
Top Quality 99.9% up Paxlovid intermediate (1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamid

Top Quality 99.9% up Paxlovid intermediate (1R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamid
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service